153 related articles for article (PubMed ID: 17434894)
1. The expanding role of PET technology in the management of patients with colorectal cancer.
Herbertson RA; Lee ST; Tebbutt N; Scott AM
Ann Oncol; 2007 Nov; 18(11):1774-81. PubMed ID: 17434894
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography and colorectal cancer.
Lin M; Wong K; Ng WL; Shon IH; Morgan M
Crit Rev Oncol Hematol; 2011 Jan; 77(1):30-47. PubMed ID: 20619671
[TBL] [Abstract][Full Text] [Related]
3. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
[TBL] [Abstract][Full Text] [Related]
4. The role of positron emission tomography in the management of recurrent colorectal cancer: a review.
Watson AJ; Lolohea S; Robertson GM; Frizelle FA
Dis Colon Rectum; 2007 Jan; 50(1):102-14. PubMed ID: 17115340
[TBL] [Abstract][Full Text] [Related]
5. [F-18 fluorodeoxyglucose positron emission tomography in colorectal carcinoma].
Jörg L; Langsteger W
Wien Med Wochenschr; 2002; 152(11-12):276-9. PubMed ID: 12138655
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography and colorectal cancer.
Arulampalam TH; Costa DC; Loizidou M; Visvikis D; Ell PJ; Taylor I
Br J Surg; 2001 Feb; 88(2):176-89. PubMed ID: 11167864
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the role of FDG PET-CT for potentially operable metastatic colorectal cancer.
Culverwell AD; Chowdhury FU; Scarsbrook AF
Abdom Imaging; 2012 Dec; 37(6):1021-31. PubMed ID: 22371087
[TBL] [Abstract][Full Text] [Related]
8. Established, emerging and future roles of PET/CT in the management of colorectal cancer.
Herbertson RA; Scarsbrook AF; Lee ST; Tebbutt N; Scott AM
Clin Radiol; 2009 Mar; 64(3):225-37. PubMed ID: 19185652
[TBL] [Abstract][Full Text] [Related]
9. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
Laurens ST; Oyen WJ
PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
[TBL] [Abstract][Full Text] [Related]
10. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
[TBL] [Abstract][Full Text] [Related]
11. Elevated tumor-to-liver uptake ratio (TLR) from
Huang J; Huang L; Zhou J; Duan Y; Zhang Z; Wang X; Huang P; Tan S; Hu P; Wang J; Huang M
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1958-1968. PubMed ID: 28812134
[TBL] [Abstract][Full Text] [Related]
12. Management of recurrent colorectal cancer with positron emission tomography.
Haji A
Br J Hosp Med (Lond); 2007 Nov; 68(11):580-3. PubMed ID: 18087843
[TBL] [Abstract][Full Text] [Related]
13. PET/CT: will it change the way that we use CT in cancer imaging?
Hicks RJ; Ware RE; Lau EW
Cancer Imaging; 2006 Oct; 6(Spec No A):S52-62. PubMed ID: 17114079
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA.
Sarikaya I; Bloomston M; Povoski SP; Zhang J; Hall NC; Knopp MV; Martin EW
World J Surg Oncol; 2007 Jun; 5():64. PubMed ID: 17555577
[TBL] [Abstract][Full Text] [Related]
16. Preoperative staging of patients with liver metastases of colorectal carcinoma. Does PET/CT really add something to multidetector CT?
Ramos E; Valls C; Martinez L; Lladó L; Torras J; Ruiz S; Gamez C; Serrano T; Fabregat J; Rafecas A
Ann Surg Oncol; 2011 Sep; 18(9):2654-61. PubMed ID: 21431987
[TBL] [Abstract][Full Text] [Related]
17. PET and PET-CT for evaluation of colorectal carcinoma.
Delbeke D; Martin WH
Semin Nucl Med; 2004 Jul; 34(3):209-23. PubMed ID: 15202102
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
[TBL] [Abstract][Full Text] [Related]
19. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography.
Ogunbiyi OA; Flanagan FL; Dehdashti F; Siegel BA; Trask DD; Birnbaum EH; Fleshman JW; Read TE; Philpott GW; Kodner IJ
Ann Surg Oncol; 1997 Dec; 4(8):613-20. PubMed ID: 9416407
[TBL] [Abstract][Full Text] [Related]
20. The clinical application of positron emission tomography to colorectal cancer management.
Arulampalam TH; Costa DC; Bomanji JB; Ell PJ
Q J Nucl Med; 2001 Sep; 45(3):215-30. PubMed ID: 11788814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
